Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 19, 2020 - Issue 10
Submit an article Journal homepage
1,352
Views
9
CrossRef citations to date
0
Altmetric
Letter to the Editor

Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?

Emanuel RaschiDepartment of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0487-7996View further author information
ORCID Icon,
Paolo CaraceniDepartment of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-1439-056XView further author information
ORCID Icon,
Elisabetta PoluzziDepartment of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyView further author information
&
Fabrizio De PontiDepartment of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-0367-9595View further author information
ORCID Icon
Pages 1367-1369 | Received 04 Aug 2020, Accepted 11 Aug 2020, Published online: 25 Aug 2020

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sepideh Tahsini Tekantapeh, Morteza Ghojazadeh, Ali Akbar Ghamari, Aida Mohammadi & Hassan Soleimanpour. (2022) Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis. Expert Review of Respiratory Medicine 16:10, pages 1109-1132.
Read now

Articles from other publishers (8)

Deepak Parchwani, Amit D Sonagra, Sagar Dholariya, Anita Motiani & Ragini Singh. (2023) COVID-19-related liver injury: Focus on genetic and drug-induced perspectives. World Journal of Virology 12:1, pages 53-67.
Crossref
Juan José Cerezo Manchado, Teodoro Iturbe Hernández, María del Carmen Martínez Pacheco, Ignacio Gil Ortega, Desirée Campoy, Tania Canals Pernas, Laia Martinez Serra, Katia Jessica Flores Aparco, Cesar Andres Velasquez Escandon, Luis García de Guadiana-Romualdo, Antonio Martinez Frances & Pavel Olivera. (2023) Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry. Clinical and Applied Thrombosis/Hemostasis 29.
Crossref
Carlotta Hoffmann, Philipp A. Gerber, Claudia Cavelti-Weder, Louisa Licht, Reham Kotb, Rania Al Dweik, Michele Cherfane, Stefan R. Bornstein & Nikolaos Perakakis. (2022) Liver, NAFLD and COVID-19. Hormone and Metabolic Research 54:08, pages 522-531.
Crossref
Reza Elahi, Parsa Karami, Amir Hossein Heidary & Abdolreza Esmaeilzadeh. (2022) An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). International Immunopharmacology 105, pages 108536.
Crossref
DA Vologzhanin, AS Golota, TA Kamilova, SV Makarenko & SG Scherbak. (2022) Liver damage in patients with COVID-19. Medicine of Extreme Situations:2022(1).
Crossref
Xinyi Wang, Jianyong Lei, Zhihui Li & Lunan Yan. (2021) Potential Effects of Coronaviruses on the Liver: An Update. Frontiers in Medicine 8.
Crossref
Fatemeh Sodeifian, Zahra Sadat Seyedalhosseini, Naghmeh Kian, Mahya Eftekhari, Shaghayegh Najari, Mehdi Mirsaeidi, Yeganeh Farsi & Mohammad Javad Nasiri. (2021) Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Frontiers in Medicine 8.
Crossref
Milo Gatti, Eleonora Turrini, Emanuel Raschi, Piero Sestili & Carmela Fimognari. (2021) Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals 14:8, pages 738.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.